Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313368422> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W4313368422 endingPage "246.12" @default.
- W4313368422 startingPage "246.12" @default.
- W4313368422 abstract "Abstract Antagonistic monoclonal antibodies targeting individual checkpoint receptors on T cells, such as CTLA-4 and PD-1, are used to treat patients with metastatic disease; however, only a subset of patients respond. Combination therapies, such as CTLA-4 blockade with agonist αOX40 mAb, are synergistic in preclinical models. αOX40/αCTLA-4 therapy synergistically enhances expression of Eomesodermin (Eomes), a transcription factor that drives CD8 T cell differentiation and memory function. We hypothesize that Eomes expression plays a critical role in the synergistic efficacy of αOX40/αCTLA-4 therapy. Compared to Eomeslo CD8 T cells, Eomeshi CD8 T cells induced by αOX40/αCTLA-4 therapy express lower levels of checkpoint receptors (PD-1, TIM-3, LAG-3) and higher levels of tumor trafficking and activation markers (CXCR3, CD44), and intratumoral cytokines (IFN-γ, TNF-α). CD8 T cell-specific Eomes−/− tumor-bearing mice did not respond to αOX40/αCTLA-4 therapy, demonstrating the necessity of Eomes expressing CD8 T cells. Interleukin-2 inducible T cell kinase (ITK) negatively regulates T cell Eomes expression following T cell receptor ligation. Thus, we asked whether enhancing T cell Eomes expression by combining ibrutinib, an FDA-approved ITK inhibitor, with αOX40/αCTLA4 therapy would further improve anti-tumor responses by increasing Eomeshi CD8 T cells. This triple combination increased CD8 T cell-specific Eomes expression, tumor-specific CD8 T cells, Ki-67 (proliferation), and Th1 cytokines (IFN-γ, TNF-α) leading to reduced tumor growth and improved survival over αOX40/αCTLA-4 alone, making ibrutinib/αOX40/αCTLA-4 a potential novel triple combination therapy." @default.
- W4313368422 created "2023-01-06" @default.
- W4313368422 creator A5006880079 @default.
- W4313368422 creator A5058978173 @default.
- W4313368422 date "2020-05-01" @default.
- W4313368422 modified "2023-09-27" @default.
- W4313368422 title "Efficacy of agonist αOX40 and antagonist αCTLA-4 cancer immunotherapy is increased by ibrutinib treatment through enhanced Eomes expression and T-cell response" @default.
- W4313368422 doi "https://doi.org/10.4049/jimmunol.204.supp.246.12" @default.
- W4313368422 hasPublicationYear "2020" @default.
- W4313368422 type Work @default.
- W4313368422 citedByCount "0" @default.
- W4313368422 crossrefType "journal-article" @default.
- W4313368422 hasAuthorship W4313368422A5006880079 @default.
- W4313368422 hasAuthorship W4313368422A5058978173 @default.
- W4313368422 hasConcept C154317977 @default.
- W4313368422 hasConcept C167672396 @default.
- W4313368422 hasConcept C202751555 @default.
- W4313368422 hasConcept C203014093 @default.
- W4313368422 hasConcept C2776090121 @default.
- W4313368422 hasConcept C2777701055 @default.
- W4313368422 hasConcept C2780674031 @default.
- W4313368422 hasConcept C502942594 @default.
- W4313368422 hasConcept C55493867 @default.
- W4313368422 hasConcept C86803240 @default.
- W4313368422 hasConcept C8891405 @default.
- W4313368422 hasConceptScore W4313368422C154317977 @default.
- W4313368422 hasConceptScore W4313368422C167672396 @default.
- W4313368422 hasConceptScore W4313368422C202751555 @default.
- W4313368422 hasConceptScore W4313368422C203014093 @default.
- W4313368422 hasConceptScore W4313368422C2776090121 @default.
- W4313368422 hasConceptScore W4313368422C2777701055 @default.
- W4313368422 hasConceptScore W4313368422C2780674031 @default.
- W4313368422 hasConceptScore W4313368422C502942594 @default.
- W4313368422 hasConceptScore W4313368422C55493867 @default.
- W4313368422 hasConceptScore W4313368422C86803240 @default.
- W4313368422 hasConceptScore W4313368422C8891405 @default.
- W4313368422 hasIssue "1_Supplement" @default.
- W4313368422 hasLocation W43133684221 @default.
- W4313368422 hasOpenAccess W4313368422 @default.
- W4313368422 hasPrimaryLocation W43133684221 @default.
- W4313368422 hasRelatedWork W2018916009 @default.
- W4313368422 hasRelatedWork W2032597637 @default.
- W4313368422 hasRelatedWork W2054101033 @default.
- W4313368422 hasRelatedWork W2055715607 @default.
- W4313368422 hasRelatedWork W2083635299 @default.
- W4313368422 hasRelatedWork W2404290847 @default.
- W4313368422 hasRelatedWork W3179304282 @default.
- W4313368422 hasRelatedWork W4288445890 @default.
- W4313368422 hasRelatedWork W4312192878 @default.
- W4313368422 hasRelatedWork W4367319921 @default.
- W4313368422 hasVolume "204" @default.
- W4313368422 isParatext "false" @default.
- W4313368422 isRetracted "false" @default.
- W4313368422 workType "article" @default.